AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 172 min read$RPRX

Coyne Terrance P. sold $646K of RPRX (indirect holdings)

Coyne Terrance P. (EVP & CFO) sold 11,002 indirectly-held shares of Royalty Pharma plc (RPRX) at an average of $58.68 ($58.59–$59.14, $0.65M total) across 2 trades on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Coyne Terrance P.
Published Aug 17, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RPRX
Neutral
high confidence
Mentioned
$RPRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RPRXNeutralLow
01

Why it matters

The disclosure updates the insider trading record for RPRX, but it does not provide new operational or financial information about the company.

02

Market read

Traders may briefly reassess sentiment around RPRX due to the CFO’s sale, but the 10b5-1 structure limits interpretive value.

03

What to watch

The filing shows the executive ended with 0 shares, but it provides no context on total holdings before the plan, tax needs, or diversification motives.

Relevance 4/10Novelty 5/10Timing: filed Aug. 17, trades executed Aug. 13 (after-hours filing impact)

Background

SEC Form 4 reports an insider transaction by Royalty Pharma plc EVP and CFO Terrance P. Coyne.

Company-level read

Ticker impact

$RPRXNeutralHigh confidence
Context

Royalty Pharma CFO Coyne sold $645,551 of RPRX shares via a 10b5-1 plan, leaving 0 shares after the Aug. 13 trades.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan; it does not include new company performance, guidance, or regulatory/contract developments.

Market effects

Sector

Minimal; insider sales in a single large pharma royalty name typically do not reset sector expectations.

Regional

Minimal; US-listed ADR-style sentiment effect only.

Global

Minimal; no cross-border deal, trial, or regulatory action described.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    Royalty Pharma plc

    Company whose shares were sold by an EVP and CFO under a 10b5-1 plan.

  • insider
    Terrance P. Coyne

    EVP and CFO who executed open-market sales totaling $645,551.21.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RPRX insider trading history →

Related articles

SEP 10
$RPRXMedAI 8/10

Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Royalty Pharma (RPRX) reported that pelacarsen failed its Phase 3 trial, shifting financial focus to Spinraza royalties. The company provided $500M to Ionis (IONS) in 2023, with $150M allocated to pelacarsen. RPRX expects to recover its investment through Spinraza, aiming for a modest return. The failure limits pelacarsen's potential upside, and recovery depends on Spinraza's performance.

insidermonkey.com2 min
SEP 8
$NVSHighAI 8/10

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Novartis AG (NYSE:NVS) stock fell sharply after its Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed the primary endpoint. The company also reported that the pelacarsen Phase 3 Lp(a)HORIZON trial for cardiovascular outcomes failed. Both Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) saw stock declines due to their ties with Novartis.

aol.com2 min
SEP 8
$NVSHighAI 8/10

Why Is Novartis Stock Falling Today? - Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty

Novartis (NYSE:NVS) stock fell sharply after Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed primary endpoint. The company also reported that the pelacarsen cardiovascular trial failed to meet its primary endpoint. Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) shares also declined due to the trial results. Novartis is evaluating the data and plans to discuss next steps with health authorities.

benzinga.com2 min
SEP 2
$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

rttnews.com2 min
SEP 1
$RPRXMedAI 8/10

Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough

Royalty Pharma (RPRX) agreed to pay Zealand Pharma $100M for future royalties on rusfertide, an experimental treatment for polycythemia vera. The deal includes a 1% royalty on global sales, with $50M paid at closing and the rest after a year. Rusfertide's FDA decision is expected in Q3 2026. RPRX's Q2 2026 royalty receipts grew 14% to $768M, and it raised its full-year guidance to $3.4B-$3.5B. The company has $9.2B in debt and expects $350M-$360M in interest payments for 2026.

insidermonkey.com2 min